Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Filgotinib in RA Patients with Inadequate Response or Naïve to Methotrexate

Filgotinib in RA Patients with Inadequate Response or Naïve to Methotrexate

Presented By
Prof. Rene Westhovens, University Hospital Leuven, Belgium
Conference
EULAR 2019
Trial
Phase 3, FINCH-3

Data from the phase 3 FINCH-1 trial suggests that use of the selective Janus kinase (JAK)1 inhibitor filgotinib may be beneficial for rheumatoid arthritis (RA) patients with a previous inadequate response to methotrexate. In FINCH-3, filgotinib in combination with methotrexate led to significant improvements in RA signs and symptoms, physical function, and patient-reported outcomes compared to methotrexate alone. Furthermore, filgotinib was well tolerated in patients with early active RA naïve to methotrexate.

Filgotinib, an orally administered and selective inhibitor of JAK1 has shown good efficacy and tolerance for RA treatment with data from two pivotal phase 3 studies being reported. The FINCH-1 trial was set up as a double-blind, active-, placebo-controlled study with 4 treatment arms. Participants (n=1,755) were randomised to receive filgotinib (200 or 100 mg/day, n=475 and n=480, respectively), the comparator adalimumab (40 mg, n=325) every 2 weeks,...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on